(NASDAQ: FDMT) 4d Molecular Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.
4d Molecular Therapeutics's earnings in 2025 is -$176,439,000.On average, 7 Wall Street analysts forecast FDMT's earnings for 2025 to be -$160,019,211, with the lowest FDMT earnings forecast at -$178,349,872, and the highest FDMT earnings forecast at -$141,753,405. On average, 6 Wall Street analysts forecast FDMT's earnings for 2026 to be -$172,174,797, with the lowest FDMT earnings forecast at -$211,703,614, and the highest FDMT earnings forecast at -$132,488,476.
In 2027, FDMT is forecast to generate -$172,943,786 in earnings, with the lowest earnings forecast at -$193,637,004 and the highest earnings forecast at -$132,951,723.